Biocon Biologics Ltd (BBL), a unit of Biocon Ltd (BIOCON), Thursday said that the U.S. Food and Drug Administration (FDA) has approved Jobevne, a biosimilar to Bevacizumab.
Bevacizumab, sold under the brand name Avastin in the U.S., is indicated to treat many types of cancers including colorectal cancer, non-small cell lung cancer, glioblastoma, among others.
The approval of Jobevne expands Biocon Biologics' biosimilar oncology portfolio in the U.S. which also includes Ogivri and Fulphila. The company also markets Bevacizumab in Europe and Canada under the name Abevmy, the company said in a statement.
In 2023, sales of bevacizumab were about $2 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.